The Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
About This Group of Stocks
Our Expert Thinking
The EU approval of Eli Lilly's Alzheimer's drug Kisunla creates a new investment ecosystem. This breakthrough validates treatments that slow cognitive decline and opens opportunities in the essential support services required for safe drug administration and patient monitoring.
What You Need to Know
This group focuses on companies providing critical services like genetic testing to identify suitable patients and advanced medical imaging to monitor for side effects. These services are mandatory requirements, not optional add-ons, creating sustained demand potential.
Why These Stocks
These companies were handpicked by professional analysts as the key players in the Alzheimer's treatment support network. They represent the specialized firms positioned to benefit from increased demand as this new class of therapies enters the market.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+200.05%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 200.05% over the next year.
Stocks Rated Buy by Analysts
11 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Breakthrough Moment
The EU approval of Kisunla marks a pivotal shift in Alzheimer's treatment, creating new demand for genetic testing and imaging services that these companies provide.
Mandatory Services
These aren't optional services but required components for safe drug administration. Every patient needs genetic testing and ongoing monitoring, creating sustained revenue streams.
First-Mover Advantage
As the first approved drug in this new class, Kisunla sets the standard for future treatments, positioning these support companies at the forefront of an emerging market.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Unlock all the stocks in this group on Nemo
Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.
Sign up in 60 seconds
Zero commission trading
SIPC-protected up to $500,000
Backed by Exinity Group
6% AER interest on uninvested cash, paid out daily
AI investment insights
Discover More Opportunities
The Robotaxi Revolution: Investing In Autonomous Driving
Tesla is launching its Robotaxi service in San Francisco, signaling a major step in commercializing autonomous vehicle technology. This move creates opportunities for companies that supply the essential hardware and software for self-driving systems.
Railroad Titans: The Transcontinental Merger
A potential merger between Union Pacific and Norfolk Southern is set to create a coast-to-coast railroad giant, reshaping the U.S. freight landscape. This consolidation could drive growth for ancillary service providers, including logistics firms and railcar manufacturers, who will support the newly integrated network.
Healthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Frequently Asked Questions
Everything you need to know about the product and billing.
See the full stock group
Download Nemo to see all stocks in this group